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Abstract
Human myeloid-lineage cells are refractory to HIV-1 infection. The Vpx proteins from HIV-2 and sooty mangabey
SIV render these cells permissive to HIV-1 infection through proteasomal degradation of a putative restriction
factor. Two recent studies discovered the cellular protein SAMHD1 to be this restriction factor, demonstrating that
Vpx induces proteasomal degradation of SAMHD1 and enhances HIV-1 infection in myeloid-lineage cells. SAMHD1
functions as a myeloid-cell-specific HIV-1 restriction factor by inhibiting viral DNA synthesis. Here we discuss the
implications of these findings in delineating the mechanisms of HIV-1 restriction in myeloid-lineage cells and the
potential role of Vpx in lentiviral pathogenesis.
Introduction
Myeloid-lineage cells, including monocytes, dendritic
cells (DCs) and macrophages, play a multifaceted role in
HIV-1 initial infection and viral dissemination; however,
these cell types are restrictive to post-entry HIV-1 infec-
tion in vitro [1,2]. For gene therapy purposes, transduc-
tion of human DCs with an HIV-1-derived lentiviral
vector can be significantly enhanced by preincubation
with virus-like particles derived from SIV [3]. Subse-
quent studies indicated that Vpx proteins from sooty
mangabey SIV (SIVsm) and HIV-2 lineages efficiently
e n h a n c eH I V - 1i n f e c t i o ni nh u m a nD C sa n dp r o m o t e
the accumulation of full-length viral DNA [4]. Further
studies from several laboratories suggested that Vpx,
similar to HIV-1 Vpr, interacts with the DCAF1 compo-
nent of the CUL4A/DDB1 and E3 ubiquitin ligase com-
plex (reviewed in [5,6]). However, only SIVsm/HIV-2
Vpx can efficiently enhance HIV-1 infection in DCs and
macrophages [5]. These studies led to the hypothesis
that Vpx targets a putative HIV-1 restriction factor for
proteasomal degradation in myeloid cells through the
E3 ubiquitin ligase complex [5,6], prompting the search
for the unknown HIV-1 restriction factor in human
myeloid cells that is counteracted by Vpx.
SIVsm, SIVsm-derived rhesus macaque SIV (SIVmac),
and HIV-2 encode both Vpr, a homologue of the HIV-1
Vpr protein, and Vpx, a protein unique to the SIVsm
lineage. vpx has likely evolved via duplication of the pri-
mate lentivirus vpr gene [5]. Early studies have demon-
strated that macaques infected with Vpx-defective
SIVmac or SIVsm had decreased viremia, impaired viral
replication, and slower AIDS progression compared to
wild-type SIV-infected animals, thus revealing the
importance of Vpx in SIV pathogenesis [7,8]. The
important role of Vpx in lentiviral infection in myeloid-
lineage cells in vitro and in vivo indicates that Vpx is
not merely a functional copy of Vpr, but may possess a
unique function. Although Vpx has been reported to
facilitate nuclear import of viral DNA [5], the precise
function of Vpx in lentiviral pathogenesis remains to be
defined.
New findings and discussion
Using mass spectrometry, Laguette et al. identified
SAMHD1 as a novel Vpx-interacting protein purified
from differentiated human monocytic THP-1 cells that
express tagged Vpx [9]. The rationale for using THP-1
cells was based on the previous work that differentiated
THP-1 cells can be rendered more permissive to HIV-1
infection by transduction of SIVsm/HIV-2 Vpx-contain-
ing virus-like particles derived from SIVmac [5].
SAMHD1 is expressed in non-permissive cells, including
THP-1 cells, primary monocytes, monocyte-derived
macrophages and DCs, while permissive CD4
+ T cells
and monocytic U937 cells do not express endogenous
SAMHD1 [9], suggesting an inverse correlation between
SAMHD1 expression and permissiveness to HIV-1
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permissive cells (THP-1 cells and DCs) alleviates HIV-1
restriction, and over-expression of SAMHD1 in permis-
sive cells (HeLa cells and U937 cells) inhibits HIV-1
infection [9].
By contrast, Hrecka and colleagues identified
SAMHD1 from HEK 293T cells expressing tagged Vpx
in a proteomic screen using multidimensional protein
identification technology [10]. They demonstrated that
Vpx relieves the inhibition of HIV-1 infection in mono-
cyte-derived macrophages by mediating proteasome-
dependent degradation of SAMHD1 through the
CUL4A/DCAF1 E3 ubiquitin ligase [10]. Both studies
confirmed that Vpx interacts with SAMHD1 and
induces proteasomal degradation of SAMHD1 in THP-1
cells or macrophages, which can be restored by treat-
ment with a proteasome inhibitor [9,10].
The HD domains have putative nucelotidase and
phosphodiesterase activities, and the highly conserved
histidine (H) and aspartic acid (D) residues are critical
for catalytic activity [11]. Indeed, Laguette et al. showed
that over-expression of a HD domain mutant SAMHD1
in U937 cells fails to restrict HIV-1, suggesting that the
phosphodiesterase activity of the HD domain is impor-
tant for the restriction function of SAMHD1. Further
analysis revealed that SAMHD1 blocks HIV-1 reverse
transcription, as silencing SAMHD1 in THP-1 cells [9]
and macrophages [10] increases the levels of viral DNA.
Together, these studies suggested that SAMHD1 is the
myeloid-cell specific HIV-1 restriction factor counter-
acted by Vpx [9,10] (Figure 1).
The new findings by Laguette et al. and Hrecka et al.
have opened the door towards understanding the poten-
tial role of SAMHD1 in lentiviral pathogenesis.
SAMHD1-mediated HIV-1 restriction in myeloid-lineage
cells protects these cells from efficient HIV-1 infection,
which likely prevents an innate immune response trig-
g e r e db yH I V - 1 .B yc o n t r a s t ,S I V s ma n dH I V - 2e n c o d e
Vpx to overcome SAMHD1-mediated restriction, which
likely induces the innate antiviral immunity to confine
viral infection in natural hosts. Thus, the interactions
between SAMHD1 and Vpx may contribute to different
consequences of HIV-1 and HIV-2 infection in humans
(Table 1). Similarly, Manel and colleagues have sug-
gested that HIV-1 restriction in DCs allows HIV-1 to
avoid the antiviral immune responses derived from DCs,
which are critical antigen presenting cells bridging the
innate and adaptive immunity [12].
The biological function of SAMHD1 is largely
unknown. SAMHD1 mutations are involved in Aicardi-
Goutières syndrome (AGS), a genetic encephalopathy
mimicking congenital viral infection [13]. SAMHD1 was
initially cloned from human DCs as an interferon (IFN)-
g-inducible gene [14] and has been proposed to act as a
negative regulator of the IFN response [13]. The cellular
exonuclease TREX1 was recently shown to bind and
digest excess cytosolic HIV-1 DNA that would otherwise
activate type I IFN expression and trigger an innate
immune response [15]. Interestingly, similar to
SAMHD1, TREX1 mutations in humans are associated
with autoimmune and inflammatory diseases, including
AGS [15]. It is currently unknown whether polymorph-
isms of SAMHD1 and TREX1 are linked to AIDS pro-
gression or whether AGS patients are more susceptible
to HIV-1 infection.
Three major retrovirus restriction factors have been
identified: APOBEC3G, TRIM5a, and tetherin [6]. HIV-1































Figure 1 Vpx interacts with the E3 ubiquitin ligase complex to
target the restriction factor SAMHD1 for proteasomal
degradation. Human myeloid-lineage cells that are non-permissive
to HIV-1 infection express high levels of SAMHD1, which appears to
act early in infection at the reverse transcription step. HIV-1 has not
evolved a viral antagonist to counter this restriction; however,
SIVsm/SIVmac and HIV-2 express Vpx to circumvent this restriction.
Vpx targets SAMHD1 using the host cell E3 ubiquitin ligase
complex, in which Vpx interacts with the DCAF1 subunit of the
CUL4A/DDB1 ubiquitin ligase to degrade SAMHD1 via the
proteasome. This allows HIV-1 reverse transcription to occur and
viral replication to complete.
Table 1 Comparison of HIV-1 and HIV-2 regarding




Vpx protein expression No Yes
Human SAMHD1 degradation No Yes
Efficient infection of myeloid cells No Yes
Triggering myeloid-cell-mediated
innate anti-viral immunity
through type I interferon
No Yes




no AIDS in natural
hosts
# It is known that cross-species transmission of sooty mangabey SIV (SIVsm) to
humans has given rise to HIV-2 [6].
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for APOBEC3G and Vpu for tetherin. These restriction
factors function across many different cell types, whereas
SAMHD1 appears to be specific to the myeloid-lineage
cells. It might be possible that SAMHD1 acts in concert
with another myeloid-specific co-factor [10]. It appears
that only Vpx from the SIVsm/HIV-2 lineage counteracts
SAMHD1-mediated HIV-1 restriction in myeloid cells
[9,10], while HIV-1 Vpr does not interact or degrade
SAMHD1 [10]. SAM domains are putative protein inter-
action modules that are capable of self-association and
binding to RNA and non-SAM domain containing pro-
teins. Given that SAMHD1 interferes with the accumula-
tion of HIV-1 reverse transcripts, one can speculate that
the SAM domain of SAMHD1 may bind HIV-1 RNA or
proteins and mediate their degradation through the HD
domain and the recruitment of the E3-ligase complex.
Further delineation of the mechanisms of SAMHD1
restriction is required to fully understand the HIV-1
restriction in myeloid-lineage cells and why HIV-1 has
not evolved a viral antagonist to counteract SAMHD1.
SAMHD1-mediated HIV-1 restriction has so far been
analyzed only in monocyte-derived DCs [9] and macro-
phages [10], and it should be investigated in primary
monocytes, myeloid DCs, as well as plasmacytoid DCs
that can produce high levels of type I IFN upon HIV-1
stimulation [1,2]. It is unclear whether SAMHD1 is also
type I IFN inducible, similar to other HIV-1 restriction
factors. It would be interesting to know whether
SAMHD1 can restrict other retroviruses, endogenous
retroviruses, or other non-retroviruses and whether
viruses use their own viral components to counteract
SAMHD1.
Conclusions
The discovery of SAMHD1 as a myeloid-cell-specific
HIV-1 restriction factor opens many intriguing ques-
tions in understanding intrinsic immunity against HIV-
1. When considering future therapeutic opportunities,
enhancement of SAMHD1 function may help hosts
develop potent innate and adaptive immune responses
to HIV-1. Further investigation of the mechanisms
underlying SAMHD1-mediated HIV-1 restriction will
shed light on the innate immune response against retro-
viruses and aid in the future development of more effec-
tive anti-HIV-1 interventions.
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